Cargando…

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids

BACKGROUND: Neuropathic pain is a complex sort of pain that is detrimental to individuals' health, both physically and mentally, but merely a small portion of them could witness pain alleviation. Mirogabalin, by distinctive binding characteristics of voltage-gated calcium channels, has won appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Hui, Lu, Jing, Duan, Yazhuo, Li, Dejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162880/ https://www.ncbi.nlm.nih.gov/pubmed/37152369 http://dx.doi.org/10.1155/2023/4893436

Ejemplares similares

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Clinical efficacy and tolerability of Gabapentinoids with current prescription patterns in patients with Neuropathic pain
por: Shaheen, Abida, et al.
Publicado: (2019)

Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
por: Tetsunaga, Tomoko, et al.
Publicado: (2020)

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
por: Baba, Masayuki, et al.
Publicado: (2019)

Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)

Mechanisms of the gabapentinoids and α (2) δ‐1 calcium channel subunit in neuropathic pain
por: Patel, Ryan, et al.
Publicado: (2016)

Lack of impact of OCTN1 gene polymorphisms on clinical outcomes of gabapentinoids in Pakistani patients with neuropathic pain
por: Shaheen, Abida, et al.
Publicado: (2022)

Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2022)

Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
por: Inage, Kazuhide, et al.
Publicado: (2020)

The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials
por: Meaadi, Jawza, et al.
Publicado: (2023)

Gabapentinoids: Gabapentin and Pregabalin for Postoperative Pain Management
por: Imani, Farnad, et al.
Publicado: (2012)

Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

A Nutritional Supplement as Adjuvant of Gabapentinoids for Adults with Neuropathic Pain following Spinal Cord Injury and Stroke: Preliminary Results
por: Raffaeli, William, et al.
Publicado: (2023)

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
por: Baba, Masayuki, et al.
Publicado: (2019)

Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Mirogabalin—A Novel Selective Ligand for the α2δ Calcium Channel Subunit
por: Zajączkowska, Renata, et al.
Publicado: (2021)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study
por: Akazawa, Tsutomu, et al.
Publicado: (2021)

Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021)

Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
por: Kimura, Yoshiyuki, et al.
Publicado: (2021)

Heme oxygenase-1 inducer and carbon monoxide–releasing molecule enhance the effects of gabapentinoids by modulating glial activation during neuropathic pain in mice
por: Godai, Kohei, et al.
Publicado: (2018)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Current Evidence on Abuse and Misuse of Gabapentinoids
por: Hägg, Staffan, et al.
Publicado: (2020)

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats
por: Kikuchi, Kasumi, et al.
Publicado: (2023)

Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2023)

Analgesic characteristics of a newly developed α(2)δ ligand, mirogabalin, on inflammatory pain
por: Komatsu, Shuji, et al.
Publicado: (2021)

The importance of cache domains in α(2)δ proteins and the basis for their gabapentinoid selectivity
por: Page, Karen M, et al.
Publicado: (2023)

Risk of respiratory depression with opioids and concomitant gabapentinoids
por: Savelloni, Julie, et al.
Publicado: (2017)

Fatalities associated with gabapentinoids in England (2004–2020)
por: Kalk, Nicola J., et al.
Publicado: (2022)

A snapshot on the usage pattern of gabapentinoids in Oman
por: Badi, Abdulaziz Said Al, et al.
Publicado: (2022)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Risk of respiratory depression with opioids and concomitant gabapentinoids [Corrigendum]
Publicado: (2018)

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
por: McAnally, Heath, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_urt8jmgq9e7lm2l016c1kvnj04